Jithin, Chacho (2018) Prospective Study on Prescribing Pattern and Short-Term Outcomes of SGLT-2 Inhibitors in a Tertiary Care Hospital. Masters thesis, KMCH College of Pharmacy, Coimbatore.
|
Text
260711418jithin_chacho.pdf Download (2MB) | Preview |
Abstract
BACKGROUND: Sodium glucose co-transporter (SGLT-2) inhibitors are new class of antidiabetic therapy and shown to reduce cardiovascular mortality and heart failure in patients with T2DM with previous CV events or established cardiovascular disease. The aim of the study was to determine the prescribing pattern and short-term outcomes of SGLT-2 inhibitors. The primary outcome was to study the effect of SGLT-2 inhibitor as an add-on to insulin. METHODS: The prospective observational study was conducted which included 315 patients receiving SGLT-2 inhibitors for the management of T2DM mellitus with eGFR ≥40ml/min/1.73m2. The study population was divided into two- SGLT-2 + insulin ±OHA and SGLT-2 + OHA, which were further sub-divided based on duration of diabetes i.e., patients with ≤5 years and >5 years of T2DM respectively. The study was followedup at 2 months and 4 months. At the time of entry, complete medical history and laboratory evaluation were obtained. Patients demographics were also considered and recorded. The change in HbA1C, FBS, RBS, body weight, BMI, and lipid profile were measured at 2 month and 4 months. The patients were interviewed to assess ADR (if any) and it was confirmed by Naranjo ADR Scale. The adherence of the patients toward the medication was assessed with Morisky patient medication adherence scale. RESULT: The study showed that empagliflozin + biguanides + insulin + DPP-4 was the most prescribed combination. The glucose lowering (HbA1c, FBS and RBS) effect was more in empagliflozin + insulin ± OHA treated patients. Body weight, BMI and LDL was found decreased while HDL was slightly increased. Hypoglycemia was the mostly reported ADR and was more in insulin treated patients. Only one case of geno-mycotic infections was reported. Insulin treated patients had lower adherence towards the medication and hypoglycemic events was more in those patients. CONCLUSION: In conclusion, SGLT-2 inhibitor (empagliflozin) was found to significantly improve glycemic parameters along with reduction in body weight, BMI, and LDL with good effect on HDL in Indian T2DM patients with mild ADR when prescribed as add-on to insulin or other OHA.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | Reg.No.261640602 |
| Uncontrolled Keywords: | Prescribing Pattern ; Short-Term Outcomes ; SGLT-2 Inhibitors ; Tertiary Care Hospital. |
| Subjects: | PHARMACY > Pharmacy Practice |
| Depositing User: | Subramani R |
| Date Deposited: | 02 Jul 2019 15:46 |
| Last Modified: | 08 Jul 2019 03:13 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/10706 |
Actions (login required)
 |
View Item |
